Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

22.85 -1.15 (-4.79%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Eliminating Some Screened Stocks ↗
Commodity prices regularly swing 25-30% or more in any given year. When this happens, the financial health of these firms can get dicey very quickly, given the amount of capital investment it requires... 
Via Talk Markets
Topics Stocks / Equities
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Critical Insights From Xencor Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Xencor Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Decoding 5 Analyst Evaluations For Xencor ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Xencor Through Analyst Insights ↗
 
Via Benzinga
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Third Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
From Xencor, Inc.
Via Business Wire
News headline image
Decoding 6 Analyst Evaluations For Xencor ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 6 Ratings For Xencor ↗
 
Via Benzinga
News headline image
Unveiling 4 Analyst Insights On Xencor ↗
 
Via Benzinga
News headline image
Xencor Announces Upcoming Change to Board of Directors
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
From Xencor, Inc.
Via Business Wire
News headline image
Recap: Xencor Q4 Earnings ↗
 
Via Benzinga
News headline image
Xencor Announces Proposed Public Offering of Common Stock
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
From Xencor, Inc.
Via Business Wire
News headline image
XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024 ↗
XNCR stock results show that Xencor missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Xencor Reports Second Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
From Xencor, Inc.
Via Business Wire
News headline image
XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024 ↗
XNCR stock results show that Xencor missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Xencor Reports First Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Appoints Bart Cornelissen as Chief Financial Officer
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
From Xencor, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.